Cancer Monoclonal Antibodies Market Size, Share, Growth Analysis, By Type (Human, Chimeric), By Application (Blood Cancer, Breast Cancer), By End-user (Hospitals, Research Institutes), By Region - Industry Forecast 2025-2032

North America dominated the cancer monoclonal antibodies market with a dominant market share of 38.51% in 2023, and the region constituted the leading market due to strategic initiatives that had a big impact on market dynamics. One such instance can be viewed in the extensive global collaboration deal inked by AbbVie and I-Mab in September 2020. The collaboration agreement seeks the further development and commercialization of lemzoparlimab, a novel anti-CD47 monoclonal antibody for the treatment of multiple malignancies. This agreement opens possibilities for future cooperation in CD47-associated therapeutic molecules and at the same time reaffirms commitments toward the development of cancer therapeutics.

The highest growth, at a CAGR of 22.2%, is expected to be recorded in the Asia Pacific region because of various multinational companies that attempt to enter this market more aggressively than before to gain more significant shares of this new territory. Such an increase in market growth is expected to be witnessed due to the rise anticipated in national and international collaborations between agencies, most specifically for countries that are developed and in those which are considered emerging. In addition, rising biosimilars usage in the region will provide far greater avenues of revenue in the forecast period. For instance, the biosimilar drug market of China has gathered solid momentum in the last two years. In 2019, by the end of the year, there were 391 biosimilar drugs in study and development within the country-more than ever number of biosimilar drugs recorded. Up to the end of December 2020, eleven biosimilar medicines, of which six were cancer medications, had gained the right to enter the Chinese market.